LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

AZN

191.24

-0.38%↓

NVS

154.48

+0.12%↑

Search

IQVIA Holdings Inc

Closed

SectorHealthcare

168.34 2.19

Overview

Share price change

24h

Current

Min

164.66

Max

171.35

Key metrics

By Trading Economics

Income

182M

514M

Sales

264M

4.4B

P/E

Sector Avg

21.054

61.417

Profit margin

11.778

Employees

93,000

EBITDA

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+38.04% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2026

Market Stats

By TradingEconomics

Market Cap

-11B

29B

Previous open

166.15

Previous close

168.34

News Sentiment

By Acuity

13%

87%

14 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 mar 2026, 22:42 UTC

Earnings

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Earnings

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Earnings

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Earnings

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Earnings

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Earnings

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Earnings

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Earnings

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Earnings

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Earnings

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Market Talk
Major News Events

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

38.04% upside

12 Months Forecast

Average 227.62 USD  38.04%

High 255 USD

Low 200 USD

Based on 16 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

14 / 351 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat